{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:52:36Z","timestamp":1771606356180,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12967-019-2047-4","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T14:03:07Z","timestamp":1567087387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-001X","authenticated-orcid":false,"given":"Gaetano","family":"Facchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Palesandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Naglieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azzurra","family":"Farnesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Borsellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gelsomina","family":"Iovane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatello","family":"Gasparro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Ricevuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"De Tursi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"De Vivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lo Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Grillone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Scavelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Sini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Pisconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Crispo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Gebbia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Maestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Buonerba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Carten\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"D\u2019Aniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"2047_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21411","author":"PC Barata","year":"2017","unstructured":"Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017. \n                    https:\/\/doi.org\/10.3322\/caac.21411\n                    \n                  .","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2047_CR2","doi-asserted-by":"publisher","first-page":"e000185","DOI":"10.1136\/esmoopen-2017-000185","volume":"2","author":"A Rodriguez-Vida","year":"2017","unstructured":"Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH. New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017;2(2):e000185. \n                    https:\/\/doi.org\/10.1136\/esmoopen-2017-000185\n                    \n                   (eCollection 2017).","journal-title":"ESMO Open."},{"issue":"2","key":"2047_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00345-016-1868-5","volume":"35","author":"J Bedke","year":"2017","unstructured":"Bedke J, Gauler T, Gr\u00fcnwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, Zastrow S, Miller K. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35(2):179\u201388. \n                    https:\/\/doi.org\/10.1007\/s00345-016-1868-5\n                    \n                  .","journal-title":"World J Urol"},{"key":"2047_CR4","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170209094030","author":"C Cavaliere","year":"2017","unstructured":"Cavaliere C, D Aniello C, Pepa CD, Pisconti S, Berretta M, Facchini G. Current and emerging treatments for metastatic renal cell carcinoma. Curr Cancer Drug Targets. 2017. \n                    https:\/\/doi.org\/10.2174\/1568009617666170209094030\n                    \n                  .","journal-title":"Curr Cancer Drug Targets."},{"key":"2047_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.14694\/EDBK_174469","volume":"37","author":"DM Gill","year":"2017","unstructured":"Gill DM, Agarwal N, Vaishampayan U. Evolving treatment paradigm in metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:319\u201329. \n                    https:\/\/doi.org\/10.14694\/EDBK_174469\n                    \n                  .","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"18","key":"2047_CR6","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1200\/JCO.2012.45.2003","volume":"32","author":"J Brugarolas","year":"2014","unstructured":"Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014;32(18):1968\u201376. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.45.2003\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"2047_CR7","first-page":"147","volume-title":"Prognostic and predictive response therapy factors in cancer disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prost ate Cancers)","author":"C Cavaliere","year":"2015","unstructured":"Cavaliere C, D\u2019Aniello C, Cecere S, Di Napoli M, Berretta M, De Domenico R, et al. Renal cancer: prognostic and predictive biomarkers. In: Islam R, editor. Prognostic and predictive response therapy factors in cancer disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prost ate Cancers). New York: Nova Science Publishers; 2015. p. 147\u201374."},{"issue":"5","key":"2047_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.cancergen.2015.02.008","volume":"208","author":"L Liao","year":"2015","unstructured":"Liao L, Testa JR, Yang H. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet. 2015;208(5):206\u201314. \n                    https:\/\/doi.org\/10.1016\/j.cancergen.2015.02.008\n                    \n                  .","journal-title":"Cancer Genet."},{"key":"2047_CR9","first-page":"e289","volume":"1","author":"C D\u2019Aniello","year":"2014","unstructured":"D\u2019Aniello C, Cavaliere C, Licchetta A, Gnoni A, Pisconti S, Facchini G. Metastatic renal cancer: prognostic and predictive biomarkers. World Cancer Res J. 2014;1:e289.","journal-title":"World Cancer Res J"},{"issue":"9807","key":"2047_CR10","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931\u20139. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(11)61613-9\n                    \n                   (Epub 2011 Nov 4).","journal-title":"Lancet"},{"issue":"6","key":"2047_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552\u201362. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70093-7\n                    \n                   (Epub 2013 Apr 16).","journal-title":"Lancet Oncol."},{"key":"2047_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.09.013","author":"S Sherman","year":"2015","unstructured":"Sherman S, Amzal B, Calvo E, Wang X, Park J, Liu Z, Lin C, Casciano R. An indirect comparison of everolimus versus axitinib in US patients with advanced renal cell carcinoma in whom prior sunitinib therapy failed. Clin Ther. 2015. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2015.09.013\n                    \n                  .","journal-title":"Clin Ther."},{"issue":"12","key":"2047_CR13","doi-asserted-by":"publisher","first-page":"e114264","DOI":"10.1371\/journal.pone.0114264","volume":"9","author":"DY Heng","year":"2014","unstructured":"Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies. PLoS ONE. 2014;9(12):e114264. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0114264\n                    \n                   (eCollection 2014. Review.\u00f9).","journal-title":"PLoS ONE"},{"key":"2047_CR14","first-page":"5","volume":"1","author":"U Basso","year":"2014","unstructured":"Basso U, Calvani N, De Giorgi U, De Tursi M, De Vivo R, Facchini G, et al. Trattamento di seconda linea del carcinoma renale metastatico me gestione del paziente: focus su axitinib. Future Oncol. 2014;1:5\u201374.","journal-title":"Future Oncol."},{"key":"2047_CR15","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.2147\/ott.s100706","volume":"9","author":"H Wang","year":"2016","unstructured":"Wang H, Man L, Li G, Huang G, Wang J. Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis. Onco Targets Ther. 2016;9:3423\u201332. \n                    https:\/\/doi.org\/10.2147\/ott.s100706\n                    \n                   (eCollection 2016).","journal-title":"Onco Targets Ther."},{"issue":"suppl_4","key":"2047_CR16","doi-asserted-by":"publisher","first-page":"iv280","DOI":"10.1093\/annonc\/mdu337.42","volume":"25","author":"P Maroto","year":"2014","unstructured":"Maroto P, Lainez N, Esteban E, Espinosa M, Juan MJ, Etxaniz O, Suarez C, Sep\u00falveda JM, Rubio G, Arranz Arija JA, Jimenez L, Saez MI, Puente J, Chirivella Gonzalez I, Gallardo E, Jurado JM, Garcia-Donas J, L\u00f3pez Brea M, Garrido M, de Soto Prado Y, Otero D. Real life efficacy and safety of axitinib (AXI) in patients with renal cell carcinoma (RCC): results from the Spanish compassionate use program. Ann Oncol. 2014;25(suppl_4):iv280\u2013304.","journal-title":"Ann Oncol."},{"issue":"2_suppl","key":"2047_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1200\/jco.2016.34.2_suppl.569","volume":"34","author":"Thomas Hutson","year":"2016","unstructured":"Hutson T, Jiao X, Wilson T, Cisar LA, MacLean EA. Axitinib treatment among patients with mRCC in a U.S. community oncology setting: a retrospective study of 135 patients. J Clin Oncol. 2016;34(suppl 2S) (abstract 569).","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"2047_CR18","doi-asserted-by":"publisher","first-page":"e1081","DOI":"10.1016\/j.clgc.2017.07.015","volume":"15","author":"A Guida","year":"2017","unstructured":"Guida A, Albiges L, Loriot Y, Massard C, Fizazi K, Escudier BJ. Everolimus (E) versus axitinib (A) as second-line therapy (2L) in metastatic renal cell carcinoma (mRCC): retrospective experience at Gustave Roussy.\u00a0Clin Genitourin Cancer.\u00a02017;15(6):e1081\u2013e1088. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2017.07.015\n                    \n                   (Epub 2017 Aug 12).","journal-title":"Clin Genitourin Cancer"},{"issue":"15_suppl","key":"2047_CR19","doi-asserted-by":"crossref","first-page":"e15535","DOI":"10.1200\/jco.2013.31.15_suppl.e15535","volume":"31","author":"UM Vogl","year":"2017","unstructured":"Vogl UM, Ponhold L, Locker GL, Zielinski C, Klingler C, Kramer G, Schmidinger M. Safety and efficacy of axitinib in pretreated patients with metastatic renal cell carcinoma: a single center experience of the Medical University of Vienna, Austria. J Clinical Oncol.\u00a02013;31(15_suppl):\u00a0e15535\u2013e15535.","journal-title":"J Clinical Oncol."},{"key":"2047_CR20","doi-asserted-by":"crossref","unstructured":"Signorovitch JE, Kumar Pal S, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ, Jonasch E. Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for 2nd targeted therapy (TT) of metastatic renal cell carcinoma (mRCC) in the US: A retrospective chart review. J Clin Oncol. 2015; 33:(suppl) (abstract e15612).","DOI":"10.1200\/jco.2015.33.15_suppl.e15612"},{"key":"2047_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ejca.2017.04.015","volume":"79","author":"M Matias","year":"2017","unstructured":"Matias M, Le Teuff G, Albiges L, Guida A, Brard C, Bacciarelo G, Loriot Y, Massard C, Lassau N, Fizazi K, Escudier B. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. Eur J Cancer. 2017;79:185\u201392. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.04.015\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"15","key":"2047_CR22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/fon-2016-0566","volume":"13","author":"TE Hutson","year":"2017","unstructured":"Hutson TE, Jiao X, Wilson T, Cisar L, MacLean EA. Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. Future Oncol. 2017;13(15):1323\u201332. \n                    https:\/\/doi.org\/10.2217\/fon-2016-0566\n                    \n                  .","journal-title":"Future Oncol."},{"issue":"1","key":"2047_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clgc.2016.06.019","volume":"15","author":"H Miyake","year":"2017","unstructured":"Miyake H, Harada KI, Ozono S, Fujisawa M. Assessment of efficacy, safety, and quality of life of 124 patients treated with axitinib as second-line therapy for metastatic renal-cell carcinoma: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15(1):122\u20138. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2016.06.019\n                    \n                  .","journal-title":"Clin Genitourin Cancer."},{"key":"2047_CR24","first-page":"331","volume":"7","author":"C D\u2019Aniello","year":"2016","unstructured":"D\u2019Aniello C, Vitale MG, Farnesi A, Calvetti L, Laterza MM, Cavaliere C, Della Pepa C, Conteduca V, Crispo A, De Vita F, Grillone F, Ricevuto E, De Tursi M, De Vivo R, Di Napoli M, Cecere SC, Iovane G, Amore A, Piscitelli R, Quarto G, Pisconti S, Ciliberto G, Maiolino P, Muto P, Perdon\u00e0 S, Berretta M, Naglieri E, Galli L, Carten\u00ec G, De Giorgi U, Pignata S, Facchini G, Rossetti S. Axitinib after sunitinib in metastatic renal cancer: preliminary results from Italian \u201cReal-World\u201d SAX study. Front Pharmacol. 2016;7:331.","journal-title":"Front Pharmacol."},{"issue":"2","key":"2047_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026\n                    \n                  .","journal-title":"Eur J Cancer."},{"issue":"11","key":"2047_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.urolonc.2017.08.010","volume":"35","author":"RK Jain","year":"2017","unstructured":"Jain RK, Gandhi S, George S. Second-line systemic therapy in metastatic renal-cell carcinoma: a review. Urol Oncol. 2017;35(11):640\u20136. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2017.08.010\n                    \n                   (Epub 2017 Sep 5).","journal-title":"Urol Oncol."},{"issue":"1","key":"2047_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-016-0374-y","volume":"10","author":"K Zarrabi","year":"2017","unstructured":"Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol. 2017;10(1):38. \n                    https:\/\/doi.org\/10.1186\/s13045-016-0374-y\n                    \n                  .","journal-title":"J Hematol Oncol."},{"key":"2047_CR28","unstructured":"Surveillance Epidemiology and End Results Program. Cancer stat facts: kidney and renal pelvis cancer. 2017. \n                    https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html\n                    \n                  . Accessed 31 Oct 2016."},{"issue":"3","key":"2047_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11864-011-0161-5","volume":"12","author":"M Extermann","year":"2011","unstructured":"Extermann M. Basic assessment of the older cancer patient. Curr Treat Options Oncol. 2011;12(3):276\u201385. \n                    https:\/\/doi.org\/10.1007\/s11864-011-0161-5\n                    \n                  .","journal-title":"Curr Treat Options Oncol"},{"key":"2047_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0628-2","author":"NJ Vogelzang","year":"2017","unstructured":"Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting pazopanib or sunitinib treatment: a retrospective medicare claims analysis. Adv Ther. 2017. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0628-2\n                    \n                  .","journal-title":"Adv Ther."},{"issue":"5","key":"2047_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.clgc.2014.02.009","volume":"12","author":"HK Khambati","year":"2014","unstructured":"Khambati HK, Choueiri TK, Kollmannsberger CK, North S, Bjarnason GA, Vaishampayan UN, Wood L, Knox JJ, Tan MH, MacKenzie MJ, Donskov F, Rini BI, Heng DY, International mRCC Database Consortium. Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. Clin Genitourin Cancer. 2014;12(5):354\u20138. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2014.02.009\n                    \n                  .","journal-title":"Clin Genitourin Cancer."},{"issue":"8","key":"2047_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12032-016-0813-1","volume":"33","author":"H Miyake","year":"2016","unstructured":"Miyake H, Harada K, Ozono S, Fujisawa M. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma. Med Oncol. 2016;33(8):95. \n                    https:\/\/doi.org\/10.1007\/s12032-016-0813-1\n                    \n                  .","journal-title":"Med Oncol"},{"issue":"8","key":"2047_CR33","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","volume":"32","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2047_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","volume":"68","author":"C Eichelberg","year":"2015","unstructured":"Eichelberg C, Vervenne WL, De Santis M, von Weikersthal LF, Goebell PJ, Lerchenm\u00fcller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Fl\u00f6rcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib\u2013sunitinib versus sunitinib\u2013sorafenib in the treatment of metastatic renal cell cancer. Eur Urol. 2015;68(5):837\u201347. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2015.04.017\n                    \n                  .","journal-title":"Eur Urol."},{"issue":"5","key":"2047_CR35","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3892\/mco.2014.323","volume":"2","author":"HW Leung","year":"2014","unstructured":"Leung HW, Chan AL, Lin SJ. Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: a network meta-analysis of randomised clinical trials. Mol Clin Oncol. 2014;2(5):858\u201364 (Epub 2014 Jun 23).","journal-title":"Mol Clin Oncol."},{"issue":"12","key":"2047_CR36","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1038\/bjc.2014.244","volume":"110","author":"B Escudier","year":"2014","unstructured":"Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014;110(12):2821\u20138. \n                    https:\/\/doi.org\/10.1038\/bjc.2014.244\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"2","key":"2047_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/annonc\/mdu552","volume":"26","author":"R Elaidi","year":"2015","unstructured":"Elaidi R, Harbaoui A, Beuselinck B, Eymard JC, Bamias A, De Guillebon E, Porta C, Vano Y, Linassier C, Debruyne PR, Gross-Goupil M, Ravaud A, Aitelhaj M, Marret G, Oudard S. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Ann Oncol. 2015;26(2):378\u201385. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu552\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"5","key":"2047_CR38","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2014.12.036","volume":"67","author":"V Gr\u00fcnwald","year":"2015","unstructured":"Gr\u00fcnwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015;67(5):952\u20138. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2014.12.036\n                    \n                  .","journal-title":"Eur Urol"},{"key":"2047_CR39","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2147\/ott.s83302","volume":"8","author":"S Qin","year":"2015","unstructured":"Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D. Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. Onco Targets Ther. 2015;8:1363\u201373. \n                    https:\/\/doi.org\/10.2147\/ott.s83302\n                    \n                   (eCollection 2015).","journal-title":"Onco Targets Ther."},{"issue":"5","key":"2047_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3111\/13696998.2015.1131705","volume":"19","author":"SK Pal","year":"2016","unstructured":"Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. J Med Econ. 2016;19(5):462\u20138. \n                    https:\/\/doi.org\/10.3111\/13696998.2015.1131705\n                    \n                  .","journal-title":"J Med Econ."},{"issue":"6","key":"2047_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.clgc.2016.04.005","volume":"14","author":"BI Rini","year":"2016","unstructured":"Rini BI, Tomita Y, Melichar B, Ueda T, Gr\u00fcnwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E. Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma. Clin Genitourin Cancer. 2016;14(6):499\u2013503. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2016.04.005\n                    \n                  .","journal-title":"Clin Genitourin Cancer."},{"issue":"1","key":"2047_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11523-014-0307-z","volume":"10","author":"BI Rini","year":"2015","unstructured":"Rini BI, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol. 2015;10(1):45\u201353. \n                    https:\/\/doi.org\/10.1007\/s11523-014-0307-z\n                    \n                   (Epub 2014 Mar 5).","journal-title":"Target Oncol."},{"issue":"12","key":"2047_CR43","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/cas.12546","volume":"105","author":"M Eto","year":"2014","unstructured":"Eto M, Uemura H, Tomita Y, Kanayama H, Shinohara N, Kamei Y, Fujii Y, Umeyama Y, Ozono S, Naito S, Akaza H, Japan Axitinib Phase II Study Group. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer Sci. 2014;105(12):1576\u201383. \n                    https:\/\/doi.org\/10.1111\/cas.12546\n                    \n                  .","journal-title":"Cancer Sci."},{"issue":"11","key":"2047_CR44","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","volume":"26","author":"JL Lee","year":"2015","unstructured":"Lee JL, Kim MK, Park I, Ahn JH, Lee DH, Ryoo HM, Song C, Hong B, Hong JH, Ahn H. Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26(11):2300\u20135. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv357\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"3","key":"2047_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.juro.2013.08.090","volume":"191","author":"BJ Atkinson","year":"2014","unstructured":"Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191(3):611\u20138. \n                    https:\/\/doi.org\/10.1016\/j.juro.2013.08.090\n                    \n                  .","journal-title":"J Urol"},{"issue":"2","key":"2047_CR46","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/annonc\/mdv589","volume":"27","author":"S Bracarda","year":"2016","unstructured":"Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B, Rainbow Group. Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2016;27(2):366. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv589\n                    \n                  .","journal-title":"Ann Oncol."},{"issue":"19","key":"2047_CR47","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/nejmoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, G\u00e9czi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814\u201323. \n                    https:\/\/doi.org\/10.1056\/nejmoa1510016\n                    \n                  .","journal-title":"N Engl J Med."},{"issue":"7","key":"2047_CR48","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/s1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(16)30107-3\n                    \n                  .","journal-title":"Lancet Oncol."},{"issue":"19","key":"2047_CR49","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/nejmoa1510665","volume":"373","author":"B Escudier","year":"2015","unstructured":"Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313. \n                    https:\/\/doi.org\/10.1056\/nejmoa1510665\n                    \n                  .","journal-title":"N Engl J Med."},{"key":"2047_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.02.010","author":"B Escudier","year":"2017","unstructured":"Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ, CheckMate 025 investigators. CheckMate 025 Randomized Phase 3 Study: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.02.010\n                    \n                  .","journal-title":"Eur Urol."},{"issue":"9","key":"2047_CR51","doi-asserted-by":"publisher","first-page":"e0184423","DOI":"10.1371\/journal.pone.0184423","volume":"12","author":"B Amzal","year":"2017","unstructured":"Amzal B, Fu S, Meng J, Lister J, Karcher H. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLoS ONE. 2017;12(9):e0184423. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0184423\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"2047_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.critrevonc.2018.10.004","volume":"139","author":"C Porta","year":"2019","unstructured":"Porta C, Szczylik C, Casciano R, Fu S, Amzal B, Lister J, Karcher H, Meng J, Neumann M, Dinet J. Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: systematic review and indirect treatment comparison. Crit Rev Oncol Hematol. 2019;139:143\u20138. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2018.10.004\n                    \n                  .","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2047_CR53","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.3747\/co.26.4595","volume":"26","author":"I Stukalin","year":"2019","unstructured":"Stukalin I, Wells JC, Graham J, Yuasa T, Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, Hansen AR, Bjarnason GA, Srinivas S, Wood LA, Alva AS, Kanesvaran R, Fu SYF, Davis ID, Choueiri TK, Heng DYC. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Curr Oncol. 2019;26(2):e175\u20139. \n                    https:\/\/doi.org\/10.3747\/co.26.4595\n                    \n                  .","journal-title":"Curr Oncol."},{"issue":"1","key":"2047_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2018.10.010","volume":"75","author":"AA Lalani","year":"2019","unstructured":"Lalani AA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. Eur Urol. 2019;75(1):100\u201310. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2018.10.010\n                    \n                  .","journal-title":"Eur Urol"},{"issue":"3","key":"2047_CR55","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1016\/j.clgc.2019.03.017","volume":"17","author":"S Bracarda","year":"2019","unstructured":"Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B. Is Axitinib still a valid option for mRCC in the second-line setting? prognostic factor analyses from the AXIS trial. Clin Genitourin Cancer. 2019;17(3):e689\u2013703. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2019.03.017\n                    \n                  .","journal-title":"Clin Genitourin Cancer."},{"issue":"10","key":"2047_CR56","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s12094-017-1657-7","volume":"19","author":"LMA Aparicio","year":"2017","unstructured":"Aparicio LMA, Fernandez IP, Cassinello J. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. Clin Transl Oncol. 2017;19(10):1175\u201382. \n                    https:\/\/doi.org\/10.1007\/s12094-017-1657-7\n                    \n                  .","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"2047_CR57","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2019-0165","volume":"24","author":"X Gao","year":"2019","unstructured":"Gao X, McDermott DF, Michaelson MD. Enhancing antitumor immunity with antiangiogenic therapy: a clinical model in renal cell carcinoma? Oncologist. 2019;24(6):725\u20137. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2019-0165\n                    \n                  .","journal-title":"Oncologist."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2047-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-2047-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2047-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T23:22:18Z","timestamp":1598570538000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-2047-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2047"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-2047-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Board of National Cancer Institute \u201cG. Pascale\u201d \u2013 IRCCS - of Napoli Italy and all patients gave consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}